Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer

Miki Gondo1, Tsutomu Sakai1, Hiroshi Tsuneoka1, Chihiro Kanehira21Department of Ophthalmology, Jikei University School of Medicine, 2Division of Radiology, Jikei University School of Medicine, Tokyo, JapanBackground: The evaluation of intravitreal bevacizumab treatment for delayed radiation maculopa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gondo M, Sakai T, Tsuneoka H, Kanehira C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f5227cc382474f8ebf9f507187229834
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f5227cc382474f8ebf9f507187229834
record_format	dspace
spelling	oai:doaj.org-article:f5227cc382474f8ebf9f5071872298342021-12-02T08:12:58ZIntravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer1177-54671177-5483https://doaj.org/article/f5227cc382474f8ebf9f5071872298342011-08-01T00:00:00Zhttp://www.dovepress.com/intravitreal-bevacizumab-for-delayed-radiation-maculopathy-and-papillo-a8181https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Miki Gondo1, Tsutomu Sakai1, Hiroshi Tsuneoka1, Chihiro Kanehira21Department of Ophthalmology, Jikei University School of Medicine, 2Division of Radiology, Jikei University School of Medicine, Tokyo, JapanBackground: The evaluation of intravitreal bevacizumab treatment for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer.Case report: A patient with radiation maculopathy and papillopathy was treated with intravitreal bevacizumab (1.25 mg). Main outcome measures included fundus photography, angiography, and optical coherence tomography (OCT). Two weeks after intravitreal bevacizumab, visual acuity improved from 0.4 to 1.2. Fundus examination revealed decreased disc swelling, peripapillary hemorrhage, and macular edema. OCT demonstrated complete resolution of serous retinal detachment. At the 12-month follow-up, there was no exudation recurrence. No ocular or systemic side effects were observed.Conclusion: Intravitreal bevacizumab can be used to treat radiation maculopathy and papillopathy. Antivascular endothelial growth factor therapy may decrease tissue injury associated with radiation vasculopathy.Keywords: bevacizumab, radiation, maculopathy, papillopathyGondo MSakai TTsuneoka HKanehira CDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 1217-1219 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Gondo M Sakai T Tsuneoka H Kanehira C Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer
description	Miki Gondo1, Tsutomu Sakai1, Hiroshi Tsuneoka1, Chihiro Kanehira21Department of Ophthalmology, Jikei University School of Medicine, 2Division of Radiology, Jikei University School of Medicine, Tokyo, JapanBackground: The evaluation of intravitreal bevacizumab treatment for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer.Case report: A patient with radiation maculopathy and papillopathy was treated with intravitreal bevacizumab (1.25 mg). Main outcome measures included fundus photography, angiography, and optical coherence tomography (OCT). Two weeks after intravitreal bevacizumab, visual acuity improved from 0.4 to 1.2. Fundus examination revealed decreased disc swelling, peripapillary hemorrhage, and macular edema. OCT demonstrated complete resolution of serous retinal detachment. At the 12-month follow-up, there was no exudation recurrence. No ocular or systemic side effects were observed.Conclusion: Intravitreal bevacizumab can be used to treat radiation maculopathy and papillopathy. Antivascular endothelial growth factor therapy may decrease tissue injury associated with radiation vasculopathy.Keywords: bevacizumab, radiation, maculopathy, papillopathy
format	article
author	Gondo M Sakai T Tsuneoka H Kanehira C
author_facet	Gondo M Sakai T Tsuneoka H Kanehira C
author_sort	Gondo M
title	Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer
title_short	Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer
title_full	Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer
title_fullStr	Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer
title_full_unstemmed	Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer
title_sort	intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/f5227cc382474f8ebf9f507187229834
work_keys_str_mv	AT gondom intravitrealbevacizumabfordelayedradiationmaculopathyandpapillopathyafterirradiationformaxillarysinuscancer AT sakait intravitrealbevacizumabfordelayedradiationmaculopathyandpapillopathyafterirradiationformaxillarysinuscancer AT tsuneokah intravitrealbevacizumabfordelayedradiationmaculopathyandpapillopathyafterirradiationformaxillarysinuscancer AT kanehirac intravitrealbevacizumabfordelayedradiationmaculopathyandpapillopathyafterirradiationformaxillarysinuscancer
_version_	1718398639515107328

Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer

Ejemplares similares